March 20, 2020
1 min read

Enrollment complete in Graybug’s phase 2b wet AMD treatment trial

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

The final patient has been enrolled in a phase 2b trial of Graybug Vision’s wet age-related macular degeneration treatment candidate, according to a press release.

The multicenter, prospective, masked, randomized ALTISSIMO trial is comparing 1 mg and 2 mg dosing regimens of GB-102, a microparticle depot formulation of the anti-VEGF sunitinib malate, administered every 6 months and aflibercept administered every 2 months.

A limited interim safety analysis of the trial, which began in September 2019, supports the company’s plan to take the 1 mg dose forward, the release said. This plan of action is expected to accelerate the final data analysis by approximately 6 months.

“We are confident that with over 40 patients receiving 1 mg of GB-102 through the 12-month endpoint, the ALTISSIMO trial will have a sufficiently large sample size to inform the design for our phase 3 program of GB-102 in wet AMD, while preserving the trial’s scientific integrity since the dosing regimen will remain masked. We expect the ALTISSIMO trial read-out to occur approximately 6 months earlier than originally planned,” Frederic Guerard, CEO of Graybug Vision, said in the release.